CMS Open Payments · Program Year 2024
Celgene Corporation
Celgene Corporation reported $88,892,365.92 across General Payments, Research, and Ownership to 60,850 physicians and teaching hospitals across 62,972 transactions.
- $88.9M
- All-tracks total
- 62,972
- Transactions
- 60,850
- Recipients
- +$1.4M
- General Payments vs PY2023
Celgene Corporation reported $88,892,365.92 across all CMS Open Payments tracks (General + Research + Ownership) to 60,850 physicians and teaching hospitals in Program Year 2024 - ranking #31 of 1,925 reporting manufacturers (0.6% of the all-tracks industry total); General Payments alone were $10,659,425.64, averaging $1.5K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer celgene-corporation Celgene Corporation
$88.9M · #31/1,925 · 0.6% industry · PY2024
- TOT $88.9M
- RANK #31
- SHARE 0.6%
- TXN 62,972
- RCP 60,850
- CAT 7
- GEN $10.7M
- ΔGEN +$1.4M
- TOP1 72.4%
- PY 2024
Volume peers
Nearest volume peer: Zimmer Biomet Holdings, Inc. ($88.6M)
Celgene Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Celgene Corporation's CMS-reported General Payments increased by $1.4M (+15.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CELGENE CORPORATIONPY2023: CELGENE CORPORATIONPY2024: Celgene Corporation. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $9,210,209.31
- PY2024
- $10,659,425.64
What the Data Shows for Celgene Corporation
Averaging $1.4K per transaction and $1.5K per recipient, Celgene Corporation's Program Year 2024 total comes to $88,892,365.92 across 62,972 transactions and 60,850 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #31 of 1,925 companies, representing 0.6% of all industry payments reported nationwide for the year.
Of the 7 general-payment categories charted below, "Royalty or License" is the largest at $7.7M across 8 transactions, 72.5% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Royalty or License" leads Celgene Corporation's 7-category general-payment breakdown at $7.7M, 72.5% of the reported total.
Celgene Corporation reports 7 general-payment categories - the top three are Royalty or License (72.5%), Food and Beverage (11.8%), and Compensation for Services Other Than Consulting (5.9%). The remaining 4 categories make up 9.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Celgene Corporation divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $7.7M | 8 | 72.5% |
| Food and Beverage | $1.3M | 59,812 | 11.8% |
| Compensation for Services Other Than Consulting | $632.0K | 21 | 5.9% |
| Travel and Lodging | $464.5K | 546 | 4.4% |
| Consulting Fee | $405.1K | 396 | 3.8% |
| Grant | $128.0K | 29 | 1.2% |
| Compensation for Faculty or Speaker (Medical Education) | $41.5K | 38 | 0.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $8,300,229.64 (77.9%) of $10,659,425.64 in this company's General Payments records across 17,126 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Celgene Corporation
The five named recipients with the highest reported General Payments from this company
- 1
Seattle Childrens Hospital
$7,718,018.00 across 5 reported transactions
- 2
Dana-Farber Cancer Institute
$314,119.50 across 3 reported transactions
- 3
University Of Kansas Hospital
$103,933.00 across 13 reported transactions
- 4
Langley Porter Psychiatric Hospital
$89,159.14 across 1 reported transactions
- 5
Hospital Of The Univ Of Penna
$75,000.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Celgene Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Celgene Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Celgene Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
CSL Behring
Abbott Laboratories
Edwards Lifesciences Corporation
Incyte Corporation
Servier BioInnovation
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.